The clinical efficacy and safety of paclitaxel combined with avastin for NSCLC patients diagnosed with malignant pleural effusion

Wang, Zhen; Zheng, Yisheng; Fang, Zhenjian

doi:10.1590/1806-9282.64.03.230

Cited by 3 publications

(5 citation statements)

References 20 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2018, Wang et al conducted an RCT investigating intrapleural Endostar combined with pemetrexed and cisplatin compared with pemetrexed and cisplatin alone in subjects with MPE from nonsquamous NSCLC. 68 The tumor response was evaluated based on version 1.1 RECIST. 62 The treatment group and control group had effective rates of 81.82 and 64.5% ( p = 0.027), MPE control rates of 93.9 and 79.0% ( p = 0.013), and recurrence rates of 9.68 and 30.6% ( p = 0.005), respectively.…”

Section: Antiangiogenic Therapymentioning

confidence: 99%

Malignant Pleural Effusions in the Era of Immunotherapy and Antiangiogenic Therapy

Wong

Fuld

Feller‐Kopman

2023

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Malignant pleural effusions (MPE) have historically been associated with a poor prognosis, and patients often require a series of invasive procedures and hospitalizations that significantly reduce quality of life at the terminus of life. However, advances in the management of MPE have coincided with the era of immunotherapies, and to a lesser extent, antiangiogenic therapies for the treatment of lung cancer. Landmark studies have shown these drugs to improve overall survival and progression-free survival in patients with lung cancer, but a paucity of phase III trial data exists for the impact of immune checkpoint inhibitors (ICI) on lung cancers associated with MPE. This review will focus on the leading studies investigating the impact of ICI and antiangiogenic therapies in patients with lung cancer and MPE. The diagnostic and prognostic values of vascular endothelial growth factor and endostatin expression levels in malignancy will also be discussed. These advancements are changing the paradigm of MPE management from palliation to treatment for the first time since 1767 when MPE was first reported. The future holds the promise of durable response and extended survival in patients with MPE.

show abstract

Section: Antiangiogenic Therapymentioning

confidence: 99%

Malignant Pleural Effusions in the Era of Immunotherapy and Antiangiogenic Therapy

Wong

Fuld

Feller‐Kopman

2023

Semin Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

“…Avastin shows good efficacy and tolerance in all of the clinical trials and thus has been approved by the U.S. Food and Drug Administration (FDA) as a first- or second-line treatment for metastatic breast cancer or as part of a combination chemotherapy scheme for metastatic colorectal cancer. Avastin is also used in glioblastoma, metastatic renal carcinoma, and NSCLC 117 . Several humanized versions of Avastin, such as Vitaxin I (MEDI-523) 118 and Abegrin (Vitaxin II, MEDI-522) have been developed, but these failed to show antitumor efficacy in clinical trials.…”

Section: Integrin Targeted Therapymentioning

confidence: 99%

Integrins as attractive targets for cancer therapeutics

Wang

et al. 2021

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Integrins are transmembrane receptors that have been implicated in the biology of various human physiological and pathological processes. These molecules facilitate cell–extracellular matrix and cell–cell interactions, and they have been implicated in fibrosis, inflammation, thrombosis, and tumor metastasis. The role of integrins in tumor progression makes them promising targets for cancer treatment, and certain integrin antagonists, such as antibodies and synthetic peptides, have been effectively utilized in the clinic for cancer therapy. Here, we discuss the evidence and knowledge on the contribution of integrins to cancer biology. Furthermore, we summarize the clinical attempts targeting this family in anti-cancer therapy development.

show abstract

“…Several studies have specifically researched the efficacy and safety of bevacizumab for the management of MPE (Table I). Among them, 6 are prospective studies (13,(24)(25)(26)(27)(28), including two phase II trials conducted by Japanese groups (24,25). Unfortunately, there is still a lack of evidence from large phase III trials to confirm the effect of bevacizumab in the management of MPE.…”

Section: Anti-angiogenic Treatment For Malignant Pleural Effusion (Mpe)mentioning

confidence: 99%

“…Three Chinese prospective studies investigated the efficacy of intrapleural bevacizumab administration in patients with MPE (26)(27)(28). Wang et al (28) enrolled 33 patients with NSCLC with MPE who all received paclitaxel and bevacizumab (5 mg/kg, intrapleurally) once every 3 weeks for 12 consecutive weeks. The total response rate of this study reached 77% (28).…”

Section: Anti-angiogenic Treatment For Malignant Pleural Effusion (Mpe)mentioning

confidence: 99%

“…Wang et al (28) enrolled 33 patients with NSCLC with MPE who all received paclitaxel and bevacizumab (5 mg/kg, intrapleurally) once every 3 weeks for 12 consecutive weeks. The total response rate of this study reached 77% (28). The median OS and median PFS times were 22.2 and 8.4 months, respectively (28).…”

Section: Anti-angiogenic Treatment For Malignant Pleural Effusion (Mpe)mentioning

confidence: 99%

See 1 more Smart Citation

Novel therapies for malignant pleural effusion: Anti‑angiogenic therapy and immunotherapy (Review)

Ding

Wen

et al. 2021

Int J Oncol

View full text Add to dashboard Cite

Patients with a variety of malignancies can develop malignant pleural effusion (MPE). MPE can cause significant symptoms and result in a marked decrease in quality of life and a poor prognosis. MPE is primarily considered as an immune and vascular manifestation of pleural metastases. In the present review, the existing evidence supporting the applicability of anti-angiogenic therapy and immunotherapy for the treatment of MPE was summarized. Patients with MPE have benefited from anti-angiogenic agents, including bevacizumab and endostar; however, no relevant prospective phase III trial has, thus far, specifically analyzed the benefit of anti-angiogenic therapy in MPE. Immunotherapy for MPE may be sufficient to turn a dire clinical situation into a therapeutic advantage. Similar to anti-angiogenic therapy, more clinical data on the efficiency and safety of immunotherapy for controlling MPE are urgently required. The combined use of anti-angiogenic therapy and immunotherapy may be a promising strategy for MPE, which requires to be further understood. Contents1. Introduction 2. Anti-angiogenic treatment for malignant pleural effusion (MPE) 3. Immunotherapy for MPE 4. Conclusion and future research direction

show abstract

The clinical efficacy and safety of paclitaxel combined with avastin for NSCLC patients diagnosed with malignant pleural effusion

Cited by 3 publications

References 20 publications

Malignant Pleural Effusions in the Era of Immunotherapy and Antiangiogenic Therapy

Malignant Pleural Effusions in the Era of Immunotherapy and Antiangiogenic Therapy

Integrins as attractive targets for cancer therapeutics

Novel therapies for malignant pleural effusion: Anti‑angiogenic therapy and immunotherapy (Review)

Contact Info

Product

Resources

About